[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552776":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":40,"collaborators":10,"id":42,"slug":10,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"different stages of individuals with Alzheimer's disease",null,[12],"Diagnostic Test: Blood biomarker",[14],{"type":15,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"DIAGNOSTIC_TEST","Blood biomarker",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Chen Zhang","CONTACT","86+83572462","chenzizm@126.com",[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Beijing","Beijing Municipality","100034","China",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":39,"role":21,"phone":10,"phoneExt":10,"email":10},"Chen Zhang, PhD",{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100552776",false,"NCT06477484","Blood Biomarkers for Screening of Alzheimer's Disease","Blood-based Biomarkers for Early Alzheimer's Disease Screening","Inclusion Criteria:\n\n* Age ≥ 50 years;\n* AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* The presence of other disorders that can cause cognitive impairment;\n* Unable to cooperate with the completion of cognitive assessment;\n* Refusal to draw blood.",true,"ALL","50 Years",{"count":52,"type":53},180,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:\n\n* to identify core blood biomarker suitable for early screening of AD.\n* to establish a comprehensive model for the early identification of AD.",[57,58],"Alzheimer's Disease","Blood Biomarkers","2024-06-26",{"date":61,"type":62},"2024-06-27","ACTUAL",{"date":64,"type":62},"2024-06-18",{"date":66,"type":53},"2026-03-26",{"name":5,"class":6},1]